Trial Profile
An Open-label Rollover Study to Continue ARRY-614 Treatment in Patients Previously Treated With ARRY-614 in Clinical Studies Sponsored by Array BioPharma Inc.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2015
Price :
$35
*
At a glance
- Drugs Pexmetinib (Primary)
- Indications Leukaemia
- Focus Therapeutic Use
- Sponsors Array BioPharma
- 03 Mar 2015 Status changed from recruiting to active, no longer recruiting according to M D Anderson Cancer centre record.
- 30 Oct 2014 New trial record